Page last updated: 2024-12-07

troxacitabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

troxacitabine: shows good anti-HIV activity without cytotoxicity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID454194
CHEMBL ID359164
CHEBI ID134886
SCHEMBL ID18548
MeSH IDM0202055

Synonyms (48)

Synonym
4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1h)-one
LTT ,
(-)-l-.b.-dioxolanec
(-)-(2s,4s)-1-[2-hydroxymethyl)-1,3-dioxolan-4-yl]cytosine
(-)-l-.beta.-dioxolane-cytosine
4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2-one
nsc668281
cis-dioxolane-c
troxacitabine (usan/inn)
145918-75-8
D06255
(-)-bch 204
troxacitabine [usan:inn]
2(1h)-pyrimidinone, 4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-
troxacitabine
(-)-occc
troxatyl
(2s-cis)-4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-2(1h)-pyrimidinone
(-)-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)cytosine
bch-4556
l-oddc
2(1h)-pyrimidinone, 4-amino-1-(-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2s-cis)-
CHEBI:134886
(-)-oddc
CHEMBL359164
lamivudine impurity i
lamivudine impurity i rs
((-))-oddc
unii-60kqz0388y
60kqz0388y ,
AKOS015967351
BCPP000031
4-amino-1-((2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)pyrimidin-2(1h)-one
lamivudine impurity i [ep impurity]
troxacitabine [inn]
troxacitabine [who-dd]
troxacitabine [usan]
lamivudine impurity i [usp impurity]
troxacitabine [mi]
DB04961
SCHEMBL18548
J-525143
4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-1,2-dihydropyrimidin-2-one
(-)-l-2',3'-dideoxy-3'-oxacytidine; troxacitabine; troxatyl
CS-0007785
HY-13770
Q7846702
2(1h)-pyrimidinone, 4-amino-1-[(2s,4s)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-

Research Excerpts

Pharmacokinetics

To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin. To identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were generated by area-moment analysis."( Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Boudinot, FD; Chu, CK; Moore, LE, 1997
)
0.3
" After treatment on the fifth day, terminal half-life values averaged 39 (63) hours, and Cl(s) was reduced by approximately 20%, averaging 127 (27) mL/min."( Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G, 2002
)
0.31
"To develop and validate a population pharmacokinetic model for troxacitabine, a novel l-nucleoside analogue, administered by short infusion; to characterize clinical covariates that influence pharmacokinetic variability; and to design a dosage rate for continuous infusion administration to achieve low micromolar concentrations, which may be more efficacious than shorter infusions."( Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK, 2006
)
0.33
"Renal function and body surface area were identified as sources of troxacitabine pharmacokinetic variability."( Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin, to identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity."( Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009
)
0.35
" Plasma and urine sampling were performed to characterize the pharmacokinetic parameters of troxacitabine in combination with cisplatin."( Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009
)
0.35
" The addition of cisplatin did not substantially alter the pharmacokinetic behavior of troxacitabine."( Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan."( Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
" The nucleoside analog was slowly absorbed after oral administration and bioavailability varied greatly between individual rats, averaging 41 +/- 27% when calculated from urinary excretion data and 37 +/- 25% when calculated from plasma OddC concentration data."( Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Boudinot, FD; Chu, CK; Moore, LE, 1997
)
0.3

Dosage Studied

The simulation results suggested that the less frequent dosing schedule of troxacitabine used currently in clinical studies was associated with less incidence of neutropenia. Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data.

ExcerptRelevanceReference
" Each rat received one dosage level of OddC and the route of administration was assessed by a randomized crossover design."( Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Boudinot, FD; Chu, CK; Moore, LE, 1997
)
0.3
" Body surface area-based dosing was statistically significantly associated with a reduction in interpatient variability in drug clearance for only five of the 33 agents: docosahexaenoic acid (DHA)-paclitaxel, 5-fluorouracil/eniluracil, paclitaxel, temozolomide, and troxacitabine."( Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Baker, SD; Donehower, RC; Grochow, LB; Rowinsky, EK; Schellens, JH; Sparreboom, A; Verweij, J, 2002
)
0.31
"To develop and validate a population pharmacokinetic model for troxacitabine, a novel l-nucleoside analogue, administered by short infusion; to characterize clinical covariates that influence pharmacokinetic variability; and to design a dosage rate for continuous infusion administration to achieve low micromolar concentrations, which may be more efficacious than shorter infusions."( Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK, 2006
)
0.33
" The population pharmacokinetic model model-derived dosage rates for continuous infusion administration successfully achieved predetermined target plasma concentrations."( Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK, 2006
)
0.33
" Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies."( A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Baccarani, M; Belanger, R; Ben-Yehuda, D; Caballero, D; Coiffier, B; Facon, T; Fanin, R; Giles, F; Gregory, SA; Panwalkar, A; Vose, JM, 2007
)
0.34
" The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, which property requires a high and frequent dosage for an intravenous administration."( Troxacitabine prodrugs for pancreatic cancer.
Adema, AD; Alexander, LE; Chu, CK; Daft, J; Hoebe, EK; Narayanasamy, J; Peters, GJ; Radi, M, 2007
)
0.34
" The simulation results suggested that the less frequent dosing schedule of troxacitabine used currently in clinical studies was associated with less incidence of neutropenia compared to more frequent dosing schedule."( Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
nucleobase-containing molecular entityAny compound that has a nucleobase as a part.
carbohydrate derivativeAny organooxygen compound derived from a carbohydrate by replacement of one or more hydroxy group(s) by an amino group, a thiol group or similar heteroatomic groups. The term also includes derivatives of these compounds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID154940Cytotoxicity against uninfected PHA-stimulated peripheral blood mononuclear (PBM) cells1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships.
AID286459Cytotoxicity against SW1573 cells after 72 hrs by SRB assay2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
AID154934Effective concentration against HIV-1 strain LAV in human peripheral blood mononuclear (PBM) cells.1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID286458Cytotoxicity against A549 cells after 72 hrs by SRB assay2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID229048Cytotoxic effect against vero cells.1993Journal of medicinal chemistry, Mar-05, Volume: 36, Issue:5
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (69)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (13.04)18.2507
2000's58 (84.06)29.6817
2010's2 (2.90)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (23.61%)5.53%
Reviews18 (25.00%)6.00%
Case Studies1 (1.39%)4.05%
Observational0 (0.00%)0.25%
Other36 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study Of Troxatyl In Patients With CML Blastic Phase Disease [NCT00012259]Phase 231 participants (Actual)Interventional2000-12-11Completed
An Open-Label, Single-Arm, Phase I Study of Troxatylâ„¢ (Troxacitabine) Administered by Continuous Infusion in Subjects With an Advanced Solid Malignancy [NCT00104286]Phase 1/Phase 250 participants Interventional2003-01-31Terminated
An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatylâ„¢ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia [NCT00104468]Phase 1/Phase 250 participants Interventional2003-04-30Terminated(stopped due to Trial stopped June 2007)
An Open-Label, Single-Arm, Multi-Center, Phase II Study of Troxatylâ„¢ (Troxacitabine) Administered by Continuous Infusion in Patients With Acute Myeloid Leukemia (AML) in Second Salvage [NCT00129948]Phase 2211 participants Interventional2005-07-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]